CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OphtiMedRx is developing a new drug for treating dry age-related macular degeneration, a major cause of vision loss. This drug, administered through an injection, targets cellular aging to slow disease progression, aiming for early intervention to preserve vision.
OphtiMedRx is an ophthalmic drug development start-up company led by a team of exceptional women physicians and scientists led by Dr.
Dana Rabinovich.
OphtiMedRx is developing a novel drug for treating dry age-related macular degeneration (AMD), a leading cause of vision loss.
There is no available treatment for dry AMD, which affects 8.7% of the population and a further 2 million diagnosed yearly.
The occurrence of AMD steadily increases with age, affecting 2% of the population at age 40 and 20…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
